BioSpace News Archive

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to one new employee consisting of an aggregate of 16,820 stock options.

Blood-based biomarker found to be viable alternative to surveillance biopsy for stable kidney transplant patients

AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), with a treatment duration of up to 24 months.2 ORIAHNN is the first FDA-approved non-surgical, oral medica

The U.S. Naval Research Laboratory Chemistry Division researchers responded within four days to the Navy’s request in early April for Coronavirus shipboard decontamination strategies.

Assure Holdings Corp., a provider of intraoperative neuromonitoring services, reported financial results for the fourth quarter and full year ended December 31, 2019.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Jefferies 2020 Healthcare Conference on June 2, 2020 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time. A live audio webcast and archi

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in abstracts to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, which will be held May 29-31, 2020.

NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 – the “Company”), today announced new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy or intolerant to cetuximab.

The U.S. Food and Drug Administration today granted approval to Oriahnn (an estrogen and progestin combination product consisting of elagolix, estradiol and norethindrone acetate) capsules, co-packaged for oral use, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

In lieu of a daily in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement